|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
12/10/2009 10:52:00 AM
CAMBRIDGE, UK, 10 DECEMBER, 2009 -- Novacta Therapeutics and O2h announced a multi FTE chemistry collaboration to support their internal drug discovery efforts. This is the third successive collaboration over the last three years.
“Following two very successful projects, we are excited to enter a third collaboration that combines the strengths of both companies.” said Dr. Sjoerd Wadman, Head of Chemistry at Novacta Therapeutics.
A view of the newly constructed lab at the 10,000 sq.m, Shirish Research Campus at Ahmedabad, India.
Sunil Shah, CEO of O2h said “We are excited to be a part of and support the research programs that Novacta is pioneering in the area of Lantibiotics and Bacteriocins. The large investment that they have received to date is testament to the scientific breakthroughs that they have made in this area”.
Novacta Therapeutics is the newly formed division of Novacta, focused exclusively on the discovery and development of novel antibacterial and antiviral agents to treat severe and difficult bacterial and viral infections. Following the appointment of a new managerial team, Novacta Therapeutics was formed in 2008 as a result of a strategic decision to focus exclusively on the company's product pipeline. Novacta developed its product pipeline based on exploiting the potent pharmacological properties of lantibiotics - a drug class that, although exhibiting superior anti-infective properties, until now has been underexploited due to the lack of adequate research tools - and bacteriocins-proteinaceous toxins produced by bacteria to inhibit the growth of similar or closely related bacterial strain(s). Further information on Novactabio can be found at www.novactabio.com.
O2h is a 5 year old discovery services company with project offices in Cambridge, UK and research campus in Ahmedabad, India. The Indian operations provide a high level of chemistry expertise while UK office provides project management support. Current clients of O2h include several top 20 pharmaceutical and biotechnology companies in the US, Europe and Japan. O2h adheres to the highest standards of performance with a particular emphasis on rapid interactive communications and delivery speed. Services provided by O2h include FTE-based synthetic chemistry, medicinal chemistry, computational chemistry, full services lab-units and ADME. Further information on O2h can be found at www.o2h.com.
|
|
|
|
|
|
|
|
|
|
|